Detalhe da pesquisa
1.
Polypharmacy and multiple sclerosis: A population-based study.
Mult Scler
; 29(1): 107-118, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36301629
2.
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis.
Mult Scler
; 29(3): 466-470, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36281835
3.
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.
J Neuroinflammation
; 19(1): 45, 2022 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35144628
4.
Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits.
Mult Scler
; 28(11): 1825-1828, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35232298
5.
Disease-modifying drugs for multiple sclerosis and subsequent health service use.
Mult Scler
; 28(4): 583-596, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34949130
6.
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
Mult Scler
; 27(2): 239-249, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32141376
7.
Patterns of comorbidities in women with breast cancer: a Canadian population-based study.
Cancer Causes Control
; 30(9): 931-941, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280456
8.
Survivorship experience: More than premature mortality from cancer.
Cancer
; 129(5): 803-804, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477910
9.
Comorbidities in Australian women with hormone-dependent breast cancer: a population-based analysis.
Med J Aust
; 208(1): 24-28, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29320669
10.
Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study.
Lancet Reg Health Am
; 29: 100667, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38269206
11.
Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis: A Multiregional Population-Based Study
Neurology
; 102(3): e208006, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38181306
12.
Health status and mental distress in people with cancer and comorbid conditions: The Australian National Health Survey analysis.
Cancer Med
; 12(16): 17225-17238, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37350767
13.
Patterns of mental health service utilisation in people with cancer compared with people without cancer: analysis of the Australian National Study of Mental Health and Wellbeing.
J Cancer Surviv
; 2023 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37792161
14.
Multiple sclerosis disease-modifying drug use by immigrants: a real-world study.
Sci Rep
; 13(1): 21235, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38040796
15.
Multiple sclerosis incidence: A systematic review of change over time by geographical region.
Mult Scler Relat Disord
; 63: 103932, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35667315
16.
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival.
Neurol Neuroimmunol Neuroinflamm
; 9(5)2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35701187
17.
Women's Health in Multiple Sclerosis: A Scoping Review.
Front Neurol
; 12: 812147, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35173669
18.
Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.
Front Immunol
; 12: 794075, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35095869
19.
Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.
Expert Rev Neurother
; 21(1): 131-140, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33146570
20.
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review.
Expert Opin Drug Saf
; 19(9): 1069-1094, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32799563